Related Experiment Video
Updated: Feb 16, 2026
09:19
Robotic Taj Mahal Hepatectomy for Hilar Cholangiocarcinoma
Published on: July 14, 2022
4.4K
NcRNAs and Cholangiocarcinoma
Zheng Wangyang1, Ji Daolin1, Xu Yi1
1Department of Hepatopancreatobiliary Surgery, Second Affiliated Hospital of Harbin Medical University.
Journal of Cancer
|January 2, 2018
Summary
Cholangiocarcinoma (CCA) involves non-coding RNAs (ncRNAs) in its development. These ncRNAs show potential as diagnostic markers and therapeutic targets for this biliary tract cancer.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Cholangiocarcinoma (CCA) is a primary biliary malignancy with a poor prognosis.
- Understanding CCA etiology and pathogenesis is limited, complicating diagnosis and therapy.
- Non-coding RNAs (ncRNAs) are increasingly implicated in CCA development.
Purpose of the Study:
- To review the role of ncRNAs in cholangiocarcinoma.
- To discuss the diagnostic and therapeutic potential of ncRNAs in CCA.
Main Methods:
- Literature review of studies on ncRNAs and CCA.
- Analysis of ncRNA expression patterns in CCA.
- Evaluation of ncRNAs as biomarkers and therapeutic targets.
Main Results:
- Deregulated expression of ncRNAs is a common feature in CCA.
- ncRNAs, including microRNAs, long non-coding RNAs, and circular RNAs, are involved in CCA pathogenesis.
- ncRNAs show promise as easily detectable biomarkers in tissues and biofluids.
Conclusions:
- ncRNA dysregulation is central to CCA development.
- ncRNAs hold significant potential for early diagnosis of CCA.
- ncRNAs represent promising targets for novel CCA therapies.
